2026 ASCO Poster: Plasma Epigenomic Profiling Identifies Mechanisms of Sensitivity and Resistance to Tepotinib in METex14 Skipping Metastatic NSCLC
2026 ASCO Poster: Plasma Epigenomic Profiling Identifies Mechanisms of Sensitivity and Resistance to Tepotinib in METex14 Skipping Metastatic NSCLC
2026 ASCO Poster: Comprehensive Epigenomic Profiling of Plasma for Non-invasive Detection of MET Activation Uncovers MET-associated Biology in Patients with EGFR-mutated Advanced NSCLC and Progression on Osimertinib
2026 ASCO Poster: Comprehensive Epigenomic Profiling of Plasma for Non-invasive Detection of MET Activation Uncovers MET-associated Biology in Patients with EGFR-mutated Advanced NSCLC and Progression on Osimerti
Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC
Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC
2026 AACR Poster: Plasma-based comprehensive epigenomic profiling enables multiplexed prediction of target gene expression and detection of resistance mechanisms
2026 AACR Poster: Plasma-based comprehensive epigenomic profiling enables multiplexed prediction of target gene expression and detection of resistance mechanisms
Precede Biosciences Launches Precede Bio Insight™, a Genome-Wide Liquid Biopsy for Functional Tumor Biology at AACR 2026
Precede Biosciences Launches Precede Bio Insight™, a Genome-Wide Liquid Biopsy for Functional Tumor Biology at AACR 2026
2026 AACR Poster: A liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2− advanced breast cancer
2026 AACR Poster: A liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2− advanced breast cancer
2026 AACR Poster: Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid biopsy stratifies endocrine therapy (ET) responders with metastatic breast cancer (MBC)
2026 AACR Poster: Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid biopsy stratifies endocrine therapy (ET) responders with metastatic breast cancer (MBC)
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform
Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer